[Cranbury, New Jersey, USA, January 16, 2026] — IVIEW Therapeutics Inc. today announced a fruitful participation at JPM Week 2026 in San Francisco, highlighted by strong investor and strategic partner engagement, insightful regulatory dialogue across multiple high-profile forums and one-to-one meetings.
During the week, Houman Hemmati, MD, PhD, Board Director and Chief Medical Advisor at IVIEW Therapeutics, successfully presented at the Biotech Showcase, a premier investor conference held during JPM Week. His presentation outlined IVIEW’s differentiated clinical-stage ophthalmology pipeline and strategic direction, with a particular focus on the company’s recent successful Phase 2a and 2b US clinical trial results for IVW-1001 eyelid wipe, an innovative eyelid-margin delivery therapy for the treatment of dry eye disease. The presentation generated strong interest and constructive dialogue with institutional investors and strategic partners.
Dr. Hemmati moderated “FDA on Personalized Medicine” session at the JPM Healthcare Conference. The session featured the Center for Drug Evaluation and Research (CDER) Acting Director Dr. Tracy Hoeg and the Center for Biologics Evaluation and Research (CBER) Director Dr. Vinay Prasad, and focused on regulatory perspectives, scientific rigor, and evolving frameworks supporting personalized and precision-based therapeutic development. The session was well attended, even it was held in the early morning at 7:30am on Jan.14.
Throughout the JPM Week, Bo Liang, PhD, MBA, Co-founder, Chairman, and Chief Executive Officer of IVIEW Therapeutics, participated in the BIO Partnering Conference and held numerous meetings with potential investors and strategic collaborators, engaging in in-depth discussions around IVIEW’s pipeline, clinical progress, and long-term growth strategy. These interactions reflected strong interest in the company’s ophthalmology-focused platform and its differentiated product pipeline, especially on phase 3 assets for the treatment of dry eye and viral conjunctivitis.
Dr. Liang participated the FDA session with Dr. Houman Hemmati, in addition, Dr. Liang participated in the JPM Peking University Forum, where he presented IVIEW Therapeutics and its strong pipeline and its IPO plan to an audience of global alumni, industry leaders, investors, and academic peers. His presentation highlighted IVIEW’s scientific vision, clinical progress, and commitment to innovation in ophthalmology, further strengthening the company’s visibility within the life sciences and academic communities.
JPM Week remains one of the most influential global gatherings for the biotechnology and life sciences industry, serving as a platform for scientific exchange, regulatory dialogue, and strategic collaboration. IVIEW Therapeutics is proud to have engaged meaningful discussions and looks forward to building on the momentum generated in San Francisco.
About IVIEW Therapeutics Inc.
IVIEW Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative ophthalmic therapies. We invest in novel mechanisms of action and differentiated drug delivery platforms to create therapies with superior clinical profiles that address significant unmet medical needs. Our pipeline includes small molecules and gene therapies for dry eye, myopia, conjunctivitis, glaucoma, and presbyopia. The U.S. headquarters is in Cranbury, New Jersey, with 11,045 square feet of combined laboratory and office space in the Princeton area.
语言：